Erste Group analyst Hans Engel downgraded AstraZeneca to Hold from Buy. The company in recent weeks has “suffered significant setbacks” in two different studies regarding the efficacy of potential drugs against lung and breast cancer, the analyst tells investors in a research note. The firm says this limits future sales growth and the further upside potential of the stock.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca’s Tagrisso gets US approval for patients with EGFRm NSLC
- AstraZeneca’s Tagrisso approved in U.S for treatment of Stage III EGFRm NSCLC
- FDA approves osimertinib for locally advanced, unresectable NSCLC after chemo
- AstraZeneca says Fasenra recommended for approval in EU by CHMP
- AstraZeneca: Datopotamab deruxtecan didn’t achieve statistical significance